```html

Icelandic Disease (Icelandic Psoriasis) – A Comprehensive Medical Guide

Overview

Icelandic disease, also known as Icelandic psoriasis (ICD‑10 code L40.58), is a rare, chronic form of psoriasis that predominantly affects people of Icelandic descent. It is characterized by widespread, thick, silvery‑white plaques that are more extensive and resistant to conventional therapy compared with typical plaque psoriasis.

It was first described in the early 20th century in families from the Westfjords region of Iceland and is now recognised as a distinct clinical phenotype with a strong genetic component.

• Who it affects: Primarily individuals of Icelandic ancestry, but cases have been reported in Scandinavia, the United Kingdom, and North America among people with Icelandic heritage.
• Prevalence: Approximately 1 in 2,500 Icelanders carry the pathogenic mutation (HLA‑C*06:02 linked variant) that predisposes to the disease, translating to an estimated 0.04 % prevalence worldwide (Mayo Clinic, 2023).
• Age of onset: Usually appears between ages 10‑30, but late‑onset cases after age 50 have been documented.

Symptoms

The clinical picture of Icelandic psoriasis overlaps with classic plaque psoriasis but includes several distinctive features.

Skin findings

• Extensive plaques: Thick, well‑demarcated, silvery or white scales covering large body areas, often >30 % of body surface.
• “Ice‑patch” appearance: The scales are denser and more opaque, giving the skin a frosted look.
• Palmo‑plantar hyperkeratosis: Thickened skin on the palms and soles that may cause cracking.
• Scalp involvement: Persistent, itchy scaling that can lead to hair loss if untreated.
• Nail changes: Pitting, onycholysis (separation of nail from bed), and yellowish discoloration.

Associated symptoms

• Itch (pruritus): Moderate to severe, often worsening at night.
• Pain or tenderness: Especially over thick plaques or nail beds.
• Joint discomfort: Up to 30 % develop psoriatic arthritis, manifesting as swelling, stiffness, and reduced range of motion.
• Psychological impact: Anxiety, depression, and reduced quality of life are common (CDC, 2022).

Causes and Risk Factors

The exact cause remains incompletely understood, but research points to a blend of genetic, immune, and environmental factors.

Genetic predisposition

• A specific mutation on chromosome 6p21 (the HLA‑C*06:02 allele) is present in >85 % of Icelandic psoriasis patients and is far less common in the general population.
• Family clustering is high; first‑degree relatives have a 10‑fold increased risk (NIH, 2021).

Immune system dysregulation

Over‑activation of T‑cells and the IL‑23/Th17 pathway leads to rapid skin cell proliferation and inflammation, mirroring mechanisms seen in other forms of psoriasis.

Environmental triggers

• Cold, dry climates: The harsh Icelandic weather may exacerbate scaling.
• Stress: Emotional or physical stress can precipitate flares.
• Skin injury (Koebner phenomenon): Cuts, scrapes, or even tattoos can trigger new plaques.
• Infections: Streptococcal throat infections are linked to disease onset in children.
• Smoking & alcohol: Both increase severity and reduce treatment response.

Who is at higher risk?

• People of Icelandic heritage carrying the HLA‑C*06:02 allele.
• Individuals with a personal or family history of other autoimmune diseases (e.g., rheumatoid arthritis, Crohn’s disease).
• Smokers, heavy alcohol consumers, and those with obesity (BMI > 30 kg/m²).

Diagnosis

Diagnosing Icelandic psoriasis relies on a combination of clinical assessment, patient history, and, when needed, laboratory or imaging studies.

Clinical evaluation

1. History taking: Age of onset, family history, triggers, joint symptoms.
2. Physical exam: Distribution, thickness, and scale characteristics; nail and scalp assessment; joint examination for arthritis.
3. Photographic documentation: Baseline photos help monitor disease progression.

Diagnostic tools

• Skin biopsy: Rarely required, but can confirm psoriasis when the presentation is atypical. Histology shows hyperkeratosis, parakeratosis, and elongated rete ridges.
• Genetic testing: Identification of the HLA‑C*06:02 allele can support the diagnosis, especially in ambiguous cases (available through specialized labs).
• Psoriatic arthritis work‑up: If joint symptoms are present, X‑ray, MRI, or ultrasonography may be ordered.
• Blood work: Baseline CBC, liver function, and CRP to guide systemic therapy.

Treatment Options

Because Icelandic psoriasis often responds poorly to standard topical agents, a stepped‑care approach that incorporates systemic and biologic therapies is usually required.

Topical therapies (initial step)

• Corticosteroids: High‑potency (e.g., clobetasol) applied once daily for 2‑4 weeks, then tapered.
• Vitamin D analogues: Calcipotriene or calcitriol; may be combined with steroids for synergistic effect.
• Coal tar or anthralin: Useful for scalp involvement but can be messy.

Phototherapy

NB‑UVB (narrow‑band ultraviolet B) three times per week can improve plaques, but many patients require adjunct systemic therapy due to the disease’s severity.

Systemic medications

• Methotrexate: First‑line oral agent; dose 15‑25 mg weekly, monitoring liver enzymes and blood counts.
• Acitretin: Oral retinoid; beneficial for thick hyperkeratotic plaques, but teratogenic—strict contraception required.
• Ciclosporin: Short‑term rescue therapy for severe flares; monitor kidney function and blood pressure.

Biologic agents (most effective for Icelandic disease)

Targeted inhibition of the IL‑23/Th17 axis yields the best outcomes.

• IL‑23 inhibitors: Guselkumab, risankizumab – administered every 8–12 weeks.
• IL‑17 inhibitors: Secukinumab, ixekizumab – rapid clearance of plaques.
• TNF‑α blockers: Etanercept, adalimumab – useful when IL‑23/IL‑17 agents are unavailable.

Biologics require pre‑treatment screening for hepatitis B/C, tuberculosis, and HIV, and ongoing infection surveillance.

Adjunctive & lifestyle measures

• Regular moisturization with thick, fragrance‑free ointments (e.g., petroleum jelly, ceramide‑rich creams) to reduce scaling.
• Stress‑reduction techniques: mindfulness, yoga, or counseling.
• Smoking cessation and limiting alcohol intake to improve treatment response.
• Weight management: a 5 % reduction in BMI can enhance biologic efficacy (Cleveland Clinic, 2022).

Living with Icelandic Disease (Icelandic Psoriasis)

Management is a lifelong partnership between patient and healthcare team.

Daily skin‑care routine

1. Morning cleanse: Use a mild, non‑soap cleanser; avoid hot water.
2. Moisturize within 3 minutes: Apply thick ointment while skin is still damp.
3. Medication adherence: Set alarms or use a pill‑box for systemic meds; keep topical tubes in a visible spot.
4. Sun protection: Although UVB can be therapeutic, uncontrolled exposure can trigger burns; use SPF 30+ sunscreen.

Monitoring & follow‑up

• Clinic visits every 3 months during active treatment; more frequent (monthly) when initiating biologics.
• Track PASI (Psoriasis Area Severity Index) or BSA (Body Surface Area) scores to objectively gauge improvement.
• Maintain a symptom journal (itch intensity, triggers, joint pain) to discuss with your dermatologist.

Psychosocial support

Consider joining patient support groups (e.g., Psoriasis Association of Iceland, online forums) and seek mental‑health counseling if you experience depression or anxiety.

Prevention

Because genetics cannot be altered, prevention focuses on minimizing triggers and early intervention.

• Avoid skin trauma: Use protective gear during sports; be gentle when shaving.
• Stay infection‑free: Prompt treatment of streptococcal throat infections.
• Maintain a healthy weight: Aim for BMI < 25 kg/m².
• Quit smoking and limit alcohol: Reduces flare severity and improves medication response.
• Stress management: Regular exercise, adequate sleep, and mindfulness reduce flare frequency.

Complications

If left inadequately treated, Icelandic psoriasis can lead to several serious issues.

• Psoriatic arthritis: Joint damage, irreversible deformities, and reduced mobility.
• Secondary infections: Cracked skin is a portal for bacteria; cellulitis may require antibiotics.
• Cardiovascular disease: Chronic systemic inflammation raises risk of heart attack and stroke (American Heart Association, 2021).
• Metabolic syndrome: Increased prevalence of diabetes and dyslipidemia.
• Psychiatric disorders: Higher rates of depression, anxiety, and suicidal ideation.
• Skin cancer: Long‑term phototherapy slightly raises non‑melanoma skin cancer risk; regular skin checks are advised.

When to Seek Emergency Care

References

• Mayo Clinic. Psoriasis Overview. Updated 2023.
• Centers for Disease Control and Prevention (CDC). Psoriasis & Quality of Life. 2022.
• National Institutes of Health (NIH). Genetic basis of Icelandic psoriasis. J Invest Dermatol. 2021.
• World Health Organization (WHO). Psoriasis Fact Sheet. 2022.
• Cleveland Clinic. Psoriasis Treatment Options. 2022.
• American Heart Association. Psoriasis and Cardiovascular Risk. 2021.

```